RUA Stock Overview
Engages in the research, development, and manufacturing of pharmaceutical products in New Zealand and internationally. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rua Bioscience Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NZ$0.031 |
52 Week High | NZ$0.15 |
52 Week Low | NZ$0.031 |
Beta | 0.23 |
11 Month Change | -34.04% |
3 Month Change | -31.11% |
1 Year Change | -78.47% |
33 Year Change | -92.05% |
5 Year Change | n/a |
Change since IPO | -95.44% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
May 13Companies Like Rua Bioscience (NZSE:RUA) Are In A Position To Invest In Growth
Dec 17Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
Jul 02Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn Situation
Mar 09Shareholder Returns
RUA | NZ Pharmaceuticals | NZ Market | |
---|---|---|---|
7D | 0% | -11.4% | 0.1% |
1Y | -78.5% | 34.7% | 9.6% |
Return vs Industry: RUA underperformed the NZ Pharmaceuticals industry which returned 34.7% over the past year.
Return vs Market: RUA underperformed the NZ Market which returned 9.6% over the past year.
Price Volatility
RUA volatility | |
---|---|
RUA Average Weekly Movement | 9.4% |
Pharmaceuticals Industry Average Movement | 11.9% |
Market Average Movement | 4.5% |
10% most volatile stocks in NZ Market | 9.3% |
10% least volatile stocks in NZ Market | 3.0% |
Stable Share Price: RUA's share price has been volatile over the past 3 months compared to the NZ market.
Volatility Over Time: RUA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | n/a | Paul Naske | www.ruabio.com |
Rua Bioscience Limited engages in the research, development, and manufacturing of pharmaceutical products in New Zealand and internationally. The company offers cannabinoid derived medicines. It is also involved in seed production and genetic discovery related activities.
Rua Bioscience Limited Fundamentals Summary
RUA fundamental statistics | |
---|---|
Market cap | NZ$5.08m |
Earnings (TTM) | -NZ$13.72m |
Revenue (TTM) | NZ$316.35k |
16.0x
P/S Ratio-0.4x
P/E RatioIs RUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RUA income statement (TTM) | |
---|---|
Revenue | NZ$316.35k |
Cost of Revenue | NZ$204.14k |
Gross Profit | NZ$112.21k |
Other Expenses | NZ$13.83m |
Earnings | -NZ$13.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.084 |
Gross Margin | 35.47% |
Net Profit Margin | -4,336.57% |
Debt/Equity Ratio | 0% |
How did RUA perform over the long term?
See historical performance and comparison